Press ReleasesÓskare Capital Announces Launch of First Medical Cannabis SEIS...

Óskare Capital Announces Launch of First Medical Cannabis SEIS & EIS Fund

-

Óskare Capital is proud to announce the launch of the first ever SEIS and EIS fund
targeting the Medical and Pharmaceutical Cannabis sector. Óskare Capital UK will advise
the Fund which is managed by Sapphire Capital Partners LLP.

The MEDCAN Fund is the first fund of its kind and will invest in both early-stage UK
companies and global companies that have the requisite operations within the UK. The
Fund aims to provide UK retail investors with access to a diversified portfolio of
companies in this rapidly growing sector.

The Enterprise Investment Scheme (EIS) and the Seed Enterprise Investment Scheme
(SEIS) are UK government initiative schemes which encourage growth and development
by granting private UK investors significant tax breaks when investing in qualifying earlystage companies.

Óskare Capital UK Director Oliver Lamb, notes, “We were motivated to set up the MEDCAN
fund with Sapphire Capital Partners LLP given that around 40% of our European dealflow
is coming from the UK, and the tax breaks investors can gain through the SEIS and EIS
schemes are significant.”

The Fund team specifically targets leading companies in the UK that have the potential to
become global champions. Examples include life sciences companies, with strong IP,
developing novel therapeutics (cannabinoids and other molecules) that target the
endocannabinoid system (“ECS”).

Discovered in 1992, ECS is found in humans and all vertebrate species, and is used as the
body’s way to maintain homeostasis and adapt to environmental stress and changes.
Cannabinoids and other novel molecules can interact with the ECS helping to address a
wide range of conditions including cancer, pain management, anxiety, epilepsy, sleep,
depression, rare diseases, ADHD and many more.

The MEDCAN Fund will also be investing in the companies that form part of the wider
medical and pharmaceutical cannabis ecosystem of services and products that support
this fast-growing global market. The Fund already has a strong pipeline of deals and will
invest in start-ups across the entire value chain (from Seed to Patient) but will not invest
in cannabis production or recreational cannabis.

One notable UK cannabis company that has gone on to become a global success story is
GW Pharmaceuticals the producer of the FDA approved cannabis-based medication
Epidiolex which was acquired by Jazz Pharmaceuticals for $7.2billion.

Óskare Capital UK Director Nicola Broughton, comments, “Whilst GW is clearly an excellent
example of a UK success story in the sector, we believe that there are opportunities in the
market with stronger intellectual property which address far wider ranges of medical
conditions that would result in even greater exits.”

Latest news

UK First As Government Allocates £500,000 Funding For Innovate Cannabis Research 

THE UK Government through its innovation agency is set to provide almost £500,000 of funding to an English company...

British People Open To Using Medical Cannabis – Yet Majority Unaware They Can Access It On Prescription 

A NEW national survey of 4,000 people has highlighted the need to improve awareness of cannabis as a medicine.  Key...

As US Hemp Cultivation Levels Plummet The Established European Industry Continues To Flourish 

DESPITE a huge decline in US hemp industry’s footprint the European industry will continue to grow, say the continent’s...

Chrystal Capital Acts As Exclusive Advisor To Change Agronomy On £9.6m Fundraise

CHRYSTAL Capital Partners LLP, is an entrepreneurial corporate finance and investment house with an established global network of Single...

European Cannabis Stocks Review: ‘End’ Of US Cannabis Bear Market Rallies European Stocks 

FOLLOWING last week’s rally there has seen something of a lull with little movement for European cannabis stocks. Last week’s...

Business of Cannabis Conference Returns to New York City on November 3rd

In this second summit, the most influential business leaders, investors and politicians gather to discuss social equity, policy and...

Must read

UK First As Government Allocates £500,000 Funding For Innovate Cannabis Research 

THE UK Government through its innovation agency is set...

As US Hemp Cultivation Levels Plummet The Established European Industry Continues To Flourish 

DESPITE a huge decline in US hemp industry’s footprint...

You might also likeRELATED
Recommended to you